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Many studies have shown that radiolabelled
antibodies and their fragments directed against
CEA are able to localise to human colonic tumours
both in experimental systems (Buchegger et al.,
1983; Rogers et al., 1985) and in patients (Mach et
al., 1981; Begent, 1985). The possibility of using
such antibodies for antibody-directed therapy of
cancer (Larson et al., 1984; Zalcberg et al., 1984)
depends on achieving a high enough effective
radiation dose at the tumour site without excessive
toxicity to normal tissues. In practice this means
increasing the dose of radiation by optimising the
specific activity of the labelled antibody without
destroying its antigen-binding capacity and
administering higher doses than have been used for
localisation. The effects of increasing the adminis-
tered dose of antibody, particularly with regard to
normal tissue accumulation, have not been
adequately addressed to date.
With therapeutic doses rapid clearance of radio-
labelled antibody from the blood pool is essential
to minimise toxicity to normal organs. In our
laboratory we are currently considering two
approaches. First, the use of a second 'clearing'
antibody which rapidly reduces the circulating level
of the primary targeting antibody after localisation
has taken place (Begent et al., 1986) and secondly
the possibility of therapy using the smaller F(ab')2
antibody fragments with their higher tumour to
normal tissue ratios over intact IgG (Rogers et al.,
1986). Both of these approaches, however, lead to a
premature net loss of radiolabel associated with the
tumour compared to the case when an equivalent
amount of intact antibody is given alone (R.B.
Pedley, unpublished result; Harwood et al., 1985).
The present studies, in the nude mouse xenograft
model, investigate whether an increased dose of a
monoclonal anti-CEA F(ab')2 fragment can help to
improve its concentration at the tumour site
without excessive accumulation in normal tissues.
Here we describe our first results.
The monoclonal antibody fragment F(ab')2-IC12
was prepared from immunopurified IC12 by the
method of Lamoyi and Nisonoff (1983) as
previously described (Harwood et al., 1985). Radio-
labelling with 1251 was carried out by the
chloramine T method to a very low specific activity
(0.6pCi ugg 1). This ensured minimal loss of
immunological activity, reduced possible de-
iodination in vivo and enabled large doses to be
used without incurring excessively high radioactivity
levels which would result in the need to add
unlabelled fragment to arrive at the different
amounts injected. The xenograft used in this study
was derived from a human colonic adenocarcinoma
cell line 'MAWI'. After implanting into nude mice
the 'MAWI' xenograft expressed moderate amounts
of CEA at the cell surface but did not secrete
measurable CEA into the mouse circulation.
Tumour weights were between 14 and 385 mg.
Tumour-bearing mice were injected in groups of
four with doses of the labelled F(ab')2-IC12 over
the range 4, 58, 117, 234 and 380,g. Groups of
mice were sacrificed and tissues excised for
counting at 4, 24 and 48h after injection. In this
preliminary study only blood and tumour were
examined. The choice of blood as an index of
normal tissue radioactivity was made since the
concentration of radiolabelled fragment in this
tissue had been shown to be higher than in any
other normal tissue except kidney (Harwood et al.,
1985). Moreover, the presence of radioactivity in
the blood is likely to be the dose limiting factor
which could induce toxicity to the bone marrow
and cause myelosuppression. The results were
calculated as the absolute concentration (jgg-1) of
F(ab')2-IC12.
The results at the 4pg dose level (Figure la)
show that by 4h after injection the tumour
accumulates approximately 0.15Mg F(ab')2-
1C12 g1 which is maintained up to 24h and then
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Figure la-d Absolute mean uptake of F(ab')2-1C12 into tumour (0 O) and blood ( 0) for
administered doses ranging from 4-380ug per mouse over the time period 4-48h after injection.The limiters
represent the s.e. variation for each group of mice.
falls to 0.09jugg- 1 by 48 h. Concentrations of
fragment in the blood were initially much higher
than that in tumour but fell rapidly to about
0.04,ygg-1 at 24h and were almost undetectable by
48 h. These results are in accordance with our
previous findings with F(ab')2-IC12 where 4.0% of
the injected dose was present g-1 tumour up to
24h after which time a net loss of fragment
occurred (Harwood et al., 1985). The rapid
clearance of the fragment from the circulation was
reflected in high tumour to blood ratios at 48h
(Table I). This phenomenon with fragments has
been well established by many laboratories
(Wilbanks et al., 1981; Buchegger et al., 1983; Wahl
et al., 1983; Harwood et al., 1985).
The effect of increasing the administered dose of
F(ab')2-1C12 on the relative concentrations in
tumour and blood are shown in Figures lb-Id. As
expected an increase in dose resulted in an increase
in the absolute concentration of label in the tumour
at each time point but the percentage of the
injected dose associated with the tumour declined.
Therefore, the higher the dose the more gradual the
increase in uptake in the tumour.
It is also noteworthy that at all dose levels
studied, circulatory clearance was incomplete at
24h but essentially complete by 48 h. However,
concentrations of label in the tumour, although
diminished, were still appreciable at 48 h after
injection. Table I summarises the effect of this on
the tumour to blood ratios which were dose
dependent at 24h and decreased with increasing
dose, but with the exception of the highest dose,
were unaffected by dose changes at 48 h. These
results stress the potential importance of circulatory
clearance mechanisms in tumour therapy and have
been discussed in the previous report (Rogers et al.,
1986).
The ratio (r) (see Table I) has been used to
denote the increased uptake of fragment in tumour
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Table I Relationship between the administered dose of
F(ab')2-lC12 and the amount present in tumour at 4, 24
and 48h after injection.
Time Dose (,ug) 4 58 117 234 380
4 T:B 0.34 0.52 - 0.35 0.32
% inj. dose 4.0 1.53 - 1.20 1.20
Uptake (ug) 0.16 0.89 - 2.80 4.50
Ratio (r) 1.00 5.50 - 17.5 28.0
24 T:B 4.40 4.20 2.80 1.90 1.70
% inj. dose 4.10 1.50 0.96 0.70 0.65
Uptake (jig) 0.16 0.87 1.12 1.64 2.47
Ratio (r) 1.00 5.40 7.0 10.2 15.4
48 T:B 13.0 15.3 - 13.0 6.2
% inj. dose 2.20 1.10 - 0.60 0.50
Uptake (jug) 0.09 0.64 - 1.40 1.90
Ratio (r) 1.00 7.0 - 15.6 21.1
Results are shown as the percentage of the injected
dose, the absolute 'uptake' in jigg-1 and as the ratio (r).
The ratio (r) denotes the increased 'uptake' as a factor
over that achieved at the 4jug dose level and was cal-
culated as
absolute 'uptake' for increased dose
absolute 'uptake' for the 4jig dose
T:B =tumour to blood ratio. The figures represent mean
values for each group of mice. Variation between mice,
ommitted for clarity, was within 12%.
with increasing doses as a factor over the uptake
achieved at the 4,ug dose. Thus at 24 and 48 h after
injection a 100-fold increase in administered
fragment resulted in a 15- and 21-fold increase in
concentration in the tumour respectively.
Although results at individual time points are
useful the data becomes more meaningful as a
guide to potential therapy if considered as a
cumulative effect over a period. We have attempted
to do this for the period 4-48 h using the data in
Figures la-Id and calculated the areas under the
Table II Relative localisation of F(ab')2-1C12 in tumour
compared to blood over the time period 4-48h after
injection.
Dose (01g) Ab At Relative localisation
4 3.7 5.0 1.35
58 22 33 1.50
234 73 80 1.10
380 109 126 1.16
Ab and A, represent the areas under the curves shown
in Figures la-d for blood and tumour respectively. The
relative localisation was calculated as At/Ab.
curves for tumour and blood (Table II). This shows
that the increasing dose levels over the range
studied do not significantly lower the relative
localisation of F(ab')2-lC12 fragments in the
tumour compared to their concentration in blood.
It is worth noting that, since the concentration of
fragment in tumour is still significant at the last
time point studied but almost cleared from the
blood, the effective localisation indicated by our
data (see Table II) up to 48h underestimates the
actual effective localisation in practice. Experiments
at time points beyond 48h need to be carried out
to confirm this.
Our experiments show that, despite the adverse
effect of dose escalation on the tumour to blood
ratios at 4 and 24h, antibody fragments may be
useful in tumour immunoradiotherapy. Our data
indicate that increased doses of F(ab')2 fragments
in man may help compensate for their reduced
concentration at the tumour site with minimal
effect on the normal tissue distribution.
The authors are grateful to Mr. G.A. Rawlins for
originating the monoclonal antibody 1C12 and to the
Cancer Research Campaign for support.
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